HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorDaping Hospital and the Research Institute of Surgery of the Third Military Medical University

About this trial

The purpose of this clinical trial is to learn the safety and efficacy of HDAC inhibitors in combination with neoadjuvant immunochemotherapy compared to neoadjuvant therapy in the treatment of locally advanced colon cancer.

The main questions it aims to answer are:

Can HDAC inhibitors combined with neoadjuvant immunochemotherapy improve the rate of pCR and complete resection in patients? Are HDAC inhibitors combined with neoadjuvant immunochemotherapy safe and reliable? Does the combination of HDAC inhibitors and neoadjuvant immunochemotherapy achieve a better long-term prognosis than neoadjuvant therapy?

Eligibility criteria

Qualifiers

Signed written informed consent to voluntarily join this study

Patients with colon cancer who are assessed by abdominal contrast-enhanced CT/abdominopelvic MRI as high-risk T3 (tumor destroys muscle wall and extends to pericolonic fat, protruding more than 5 mm into adjacent mesenteric fat) or T4 (tumor penetrates the visceral peritoneal surface or directly invades or adheres to adjacent organs or structures).

Adenocarcinoma of the colon confirmed by histopathological examination.

At least 18 years old, male or female.

Disqualifiers

History of previous allergy to monoclonal antibodies, any component of HDACi, and capecitabine;

Received any treatment against the mechanism of action of tumor immunity, such as immunization, HDACi, etc.

Immunosuppressive drugs, or systemic hormonal drugs within 2 weeks prior to the first use of the study drug to achieve immunosuppressive purposes

Receipt of a live attenuated vaccine within 4 weeks prior to the first use of study drug;

Trial design

Treatments tested in this trial

  • Chidamide + Tislelizumab + chemotherapy (CapeOX )
  • CapeOX

Treatment groups

100 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Lead sponsor

Southwest Hospital, China

Collaborator

Xinqiao Hospital of Chongqing

Collaborator

First Affiliated Hospital of Chongqing Medical University

Collaborator

The Second Affiliated Hospital of Chongqing Medical University

Collaborator

Chongqing Medical University

Collaborator

Chongqing University Cancer Hospital

Collaborator

Chongqing General Hospital

Collaborator

Chongqing Traditional Chinese Medicine Hospital

Collaborator

Chongqing Shapingba District People's Hospital

Collaborator

Chongqing Seventh People's Hospital

Collaborator

Chongqing Renji Hospital, University of Chinese Academy of Sciences

Collaborator

The 13th People's Hospital of Chongqing

Collaborator